Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03761069
Title Study of PTC299 in Relapsed/Refractory Acute Leukemias
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors PTC Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Rocky Mountain Cancer Center Aurora Colorado 80012 United States Details
Yale University New Haven Connecticut 06510 United States Details
Henry Ford Health System Detroit Michigan 48202 United States Details
Rutgers, Cancer Institute of NJ New Brunswick New Jersey 08903 United States Details
Columbia New York New York 10032 United States Details
University of Rochester MC Rochester New York 14642 United States Details
Duke Cancer Center Durham North Carolina 27710 United States Details
Gabrail Cancer Center Canton Ohio 44718 United States Details
Oncology Hematology Care, Inc. Cincinnati Ohio 45236 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Rhode Island, Miriam Hospital Providence Rhode Island 02903 United States Details
SCRI Tennessee Oncology Nashville Tennessee 37203 United States Details
Texas Oncology, P.A. Austin Texas 78705 United States Details
Texas Oncology, P.A. Fort Worth Texas 76104 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Texas Oncology, P.A. - San Antonio Medical Center San Antonio Texas 78240 United States Details
Swedish Cancer Institute Seattle Washington 91804 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field